Roland Fisch und Zitiert - Info zur Person

(1 - 6 von 7

)

A methodological framework for drug development in rare ...ScienceDirect

www.sciencedirect.com

von P Nony · · Zitiert von: 2 — Chabaud, Catherine Chiron, Catherine Cornu, Frank Dufour, Nathalie Eymard, Roland Fisch,. Renzo Guerrini, Vincent Jullien, Behrouz Kassai, Polina Kurbatova, ...

Bayesian Design of Proof-of-Concept Trials | SpringerLink

link.springer.com

von R Fisch · · Zitiert von: 41 — Roland Fisch, PhD1, Ieuan Jones, BSc1, Julie Jones, MSc1,. Jouni Kerman, PhD1, Gerd Karl Rosenkranz, PhD1, and Heinz Schmidli, PhD1. Abstract. › content › pdf

Bayesian Design of Proof-of-Concept TrialsNational Institutes of Health (.gov)

pubmed.ncbi.nlm.nih.gov

von R Fisch · · Zitiert von: 46 — Authors. Roland Fisch , Ieuan Jones , Julie Jones , Jouni Kerman , Gerd Karl Rosenkranz , Heinz Schmidli. Affiliation.

A physiologically based pharmacokinetic model for clobazam ...

pubmed.ncbi.nlm.nih.gov

von K Ogungbenro · · Zitiert von: 9 — ... Frank Dufour, Nathalie Eymard, Roland Fisch, Renzo Guerrini, Vincent Jullien, Behrouz Kassaï, Patrice Nony, Kayode Ogungbenro, David Pérol, Gérard Pons, ... › ...

Efficiency indicators for new drugs approved by the fda Gale

go.gale.com

von R Belleli · · Zitiert von: 7 — Gale Academic OneFile includes Efficiency indicators for new drugs approved by the fda by Rossella Belleli, Roland Fisch, and Tho. Click to explore. › i.do

Experimental designs for small randomised clinical trials

hal.inria.fr

von C Cornu · · Zitiert von: 111 — Catherine Cornu 1, 2, 3, * Behrouz Kassai 1, 2, 3 Roland Fisch 4 Catherine Chiron 5 Corinne Alberti 6 Renzo Guerrini 7 Anna Rosati 7 Gerard Pons 5 Harm ... › inserm